Zynex Stock Up 10.0 %
NASDAQ ZYXI opened at $8.58 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.07 and a current ratio of 3.67. The company has a market capitalization of $335.05 million, a P/E ratio of 17.51 and a beta of 0.81. Zynex has a one year low of $4.97 and a one year high of $14.24. The stock has a 50 day moving average price of $7.67 and a 200-day moving average price of $7.07.
Zynex (NASDAQ:ZYXI – Get Rating) last posted its earnings results on Thursday, April 28th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.02). The firm had revenue of $31.08 million for the quarter, compared to the consensus estimate of $30.88 million. Zynex had a net margin of 13.98% and a return on equity of 28.38%. As a group, equities analysts predict that Zynex will post 0.43 EPS for the current fiscal year.
Institutional Trading of Zynex
Zynex Company Profile
Zynex, Inc, through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device.
- Get a free copy of the StockNews.com research report on Zynex (ZYXI)
- MarketBeat: Week in Review 7/25 – 7/29
- Procter’s Earnings Start To Show Weakness In Q4
- The One Question You Have to Ask Before Investing in INTC Stock
- Home Depot: A Beautiful Boring Stock to Navigate a Bear Market
- Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.